

Full-length article

Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca^{2+} uptake/release

Hong-xia GUO^{2,3}, Feng WANG^{2,3}, Kun-qian YU³, Jing CHEN³, Dong-lu BAI³, Kai-xian CHEN³, Xu SHEN^{3,4,5}, Hua-liang JIANG^{3,4,5}

³Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 201203, China; ⁴School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China

Key words

cyclophilin; quinoxalines; surface plasmon resonance; mitochondrial permeability transition; fluorescence titration; inhibitor

¹Project supported by the State Key Program for Basic Research of China (No 2004CB-518905), the National High Technology Research and Development Program of China (No 2002AA33011 and 2005AA235030), the National Natural Science Foundation of China (No 20372069 and 20472095), and the Shanghai Basic Research Project from the Shanghai Science and Technology Commission (No 03DZ19212 and 03DZ19228).

²These authors contributed equally.

⁵Correspondence to Dr Hua-liang JIANG.
Phn 86-21-5080-6600, ext 1210.
Fax 86-21-5080-7088.

E-mail hljiang@mail.shnc.ac.cn

Dr Xu SHEN, Phn/Fax 86-21-5080-6918.

E-mail xshen@mail.shnc.ac.cn

Received 2005-04-27

Accepted 2005-06-10

doi: 10.1111/j.1745-7254.2005.00189.x

Introduction

Apoptosis is essential for normal development and aging in multicellular organisms, and abnormal regulation of apoptosis can result in multiple human diseases. Mitochondria release apoptogenic proteins such as cytochrome C and apoptosis-inducing factor (AIF) into the cytosol, which are involved in the signaling pathway of caspases and induce cell apoptosis^[1–3]. One major pathway of the release of the apoptogenic factors to the cytosol is via the rupture of the outer mitochondrial membrane due to mitochondrial permeability transition (MPT) pore opening^[3]. It is suggested that MPT pores play a potent role in cell aging^[4,5], and opening

Abstract

Aim: To investigate methods for identifying specific cyclophilin D (CypD) inhibitors derived from quinoxaline, thus developing possible lead compounds to inhibit mitochondrial permeability transition (MPT) pore opening. **Methods:** Kinetic analysis of the CypD/inhibitor interaction was quantitatively performed by using surface plasmon resonance (SPR) and fluorescence titration (FT) techniques. IC_{50} values of these inhibitors were determined by PPIase inhibition activity assays. **Results:** All the equilibrium dissociation constants (K_D) of the seven compounds binding to CypD were below 10 $\mu\text{mol/L}$. The IC_{50} values were all consistent with the SPR and FT results. Compounds GW2, 5, 6, and 7 had high inhibition activities against Ca^{2+} -dependent rat liver mitochondrial swelling and Ca^{2+} uptake/release. Compound GW5 had binding selectivity for CypD over CypA. **Conclusion:** The agreement between the measured IC_{50} values and the results of SPR and FT suggests that these methods are appropriate and powerful methods for identifying CypD inhibitors. The compounds we screened using these methods (GW1–7) are reasonable CypD inhibitors. Its potent ability to inhibit mitochondrial swelling and the binding selectivity of GW5 indicates that GW5 could potentially be used for inhibiting MPT pore opening.

of the MPT pores may cause changes in mitochondrial shape and function, such as the massive swelling of mitochondria, rupture of the outer membrane and release of inter-membrane components that induce apoptosis. It has been reported that the agents that inhibit MPT may have therapeutic potential for the treatment of human diseases such as ischemia-reperfusion injury in peripheral organs, trauma and neurodegenerative diseases^[5–7].

Recent studies have shown that the MPT pore is composed of three major proteins: the voltage-dependent anion channel (VDAC) in the outer membrane that forms a large H_2O -filled pore with a diameter of 2.5–3.0 nm, the adenine nucleotide translocator (ANT) that mediates the ADP-ATP


exchange in the inner membrane, and cyclophilin D (CypD)^[8]. CypD belongs to the family of highly homologous peptidyl prolyl *cis-trans* isomerases (PPIases) that are thought to be important for protein folding, and can bind to the immunosuppressor cyclosporin A (CSA)^[9,10]. It is known that CypD is a mitochondrial-targeted PPIase, even though its specific physiological role is largely obscure^[11,12]. CypD has been confirmed to play a decisive role in MPT pore regulation, and PPIase activity of CypD might be a necessary step in MPT pore opening^[8,13]. A model was recently proposed concerning the mechanism of permeability transition-related cytochrome c release, whereby the Ca²⁺ requirement for the induction of the MPT pore opening might be due to the Ca²⁺-dependent interaction between CypD and ANT^[14–16]. It has been reported that CypD inhibitor CSA and its analogues may block MPT pore opening^[17,18], which thereby makes discovering the CypD inhibitor an appealing project. However, to our knowledge, investigating the small molecular CypD-specific inhibitor for allowing brain penetration is still a

challenge.

In this paper, we report 7 novel quinoxaline derivatives (Scheme 1 and Figure 1) that inhibit the PPIase activity of CypD. By using surface plasmon resonance (SPR) and fluorescence titration techniques, the kinetics of the CypD-inhibitor interaction was investigated. The compounds' inhibition effects against rat liver Ca²⁺-dependent mitochondrial swelling and Ca²⁺ uptake/release were also determined. The binding selectivity of CypD over CypA for the tested compounds was analyzed, and explained based on the molecular docking technique. We hope that this research will provide a useful approach for the discovery of cyclophilin D inhibitors, and thus help to develop promising compounds using CypD as a drug target for the inhibition of MPT pore opening.

Materials and methods

All solvents and reagents were purchased commercially and were used without further purification. ¹H nuclear mag-



Scheme 1. General synthetic procedure for the seven tested compounds (GW1–7).




Figure 1. Chemical structures of GW1–7. GW1: R=ethoxy; GW2: R=diethylamino; GW3: R=3-((R)-ethoxycarbonyl) piperidino; GW4: R=3-((S)-ethoxycarbonyl) piperidino; GW5: R=pyrrolidin-1-yl; GW6: R=morpholino; GW7: R=*N,N*-diisopropylamino.

netic resonance (NMR) spectra (400 MHz) were recorded on a Varian (Palo Alto, California, USA) Mercury-400 spectrometer. Plasmid extraction was performed using the GenElute Plasmid Miniprep Kit (Sigma-Aldrich, St Louis, Missouri, USA).

The compound 6-amino-2,3-di(furan-2-yl)quinoxaline was synthesized according to the patented method^[19]. (*R*)-ethyl nipecotate and (*S*)-ethyl nipecotate were prepared according to a previously published method^[20].

General preparation procedure of compounds GW1–7

The chemical structures of the seven tested compounds are shown in Figure 1, and the general synthetic procedure is shown in Scheme 1. Briefly, the compounds were prepared from 2,4-dinitroaniline in five steps.

2,3-di(furan-2-yl)-6-ethoxycarbonylamino quinoxaline (GW1) To a solution of 6-amino-2,3-di(furan-2-yl)quinoxaline (83.1 mg, 0.30 mmol) and triethylamine (100 μ L, 0.72 mmol) in dichloromethane (10 mL) we added triphosgene (30 mg, 0.10 mmol) while stirring. The mixture was stirred at room temperature for 1 h, then ethanol (100 μ L, 1.7 mmol) was added. After another 1 h of stirring, the solvent was evaporated in a vacuum to give the crude product, which was further purified by flash column chromatography on a silica gel using petro-ether/ethyl acetate (3:1) as the eluent. The obtained compound GW1 (45.2 mg, 43% yield) was a yellowish amorphous solid. ¹H NMR (CDCl₃, 400 MHz). δ : 8.10 (d, 1H, *J*=2.4 Hz), 8.05 (d, 1H, *J*=9.1 Hz), 7.87 (dd, 1H, *J*=2.2 Hz, 9.1 Hz), 7.60 (m, 2H), 7.17 (s, 1H), 6.62 (m, 2H), 5.54 (m, 2H), 4.28 (q, 2H, *J*=7.0 Hz), 1.32 (t, 3H, *J*=7.0 Hz); IR (KBr): 3419, 3246, 2982, 2928, 1732, 1622, 1572, 1539, 1495, 1261, 1226 per cm; High-resolution mass spectra (electron impact) calculated value [HRMS(EI) Calcd] for C₁₉H₁₅N₃O₄ 349.1063; Found 349.1068.

2,3-di(furan-2-yl)-6-*N*-(*N*',*N*'-diethylcarbamoyl)amino quinoxaline (GW2) GW2 was synthesized by using a method similar to that described for the preparation of GW1, except that diethylamine was used instead of ethanol. GW2 is a brown amorphous solid (63.0 mg, 56% yield). ¹H NMR (CDCl₃, 400 MHz). δ : 8.03 (d, 2H, *J*=1.8 Hz), 7.96 (d, 1H, *J*=1.0 Hz), 7.59 (dd, 2H, *J*=0.7 Hz, 1.0 Hz), 6.78 (s, 1H), 6.61 (ddd, 2H, *J*=0.7 Hz, 3.5 Hz, 12.2 Hz), 6.54 (m, 2H), 3.42 (q, 4H, *J*=7.2 Hz), 1.25 (t, 6H, *J*=7.2 Hz); IR (KBr): 3440, 3114, 2972, 2929, 1649, 1524, 1491, 1429, 1265 per cm; HRMS (EI) Calcd for C₂₁H₂₀N₄O₃ 376.1535; Found 376.1528.

2,3-di(furan-2-yl)-6-((*R*)-3-ethoxycarbonyl-piperidino) carbonylamino quinoxaline (GW3) GW3 was prepared by using a method similar to that described for the preparation of GW1, except that (*R*)-ethyl nipecotate was used instead of ethanol. GW3 is a yellow amorphous solid (66.4 mg, 48% yield). ¹H NMR (CDCl₃, 400 MHz). δ : 8.13 (s, 1H), 8.02 (m,

1H), 7.95 (m, 2H), 7.59 (m, 2H), 6.59 (m, 2H), 6.53 (m, 2H), 4.22 (m, 2H), 3.99 (m, 2H), 3.48 (dd, 1H, *J*=3.3, 14.2 Hz), 3.10 (m, 1H), 2.70 (m, 1H), 2.20 (m, 1H), 1.45–1.95 (m, 3H), 1.29 (t, 3H, *J*=6.1 Hz); IR (KBr): 3404, 2937, 2860, 1728, 1649, 1570, 1527, 1473, 1431, 1256 cm⁻¹; HRMS(EI) Calcd for C₂₅H₂₄N₄O₅ 460.1747; Found 460.1725. [α]_D²⁰ = -52° (c=0.83, CH₃OH).

2,3-di(furan-2-yl)-6-((*S*)-3-ethoxycarbonyl-piperidino) carbonylamino quinoxaline (GW4) GW4 was prepared by using a method similar to that described for GW1 except that (*S*)-ethyl nipecotate was used instead of ethanol. GW4 was a yellow amorphous solid (68.7 mg, 50% yield). ¹H NMR (CDCl₃, 400 MHz). δ : 8.13 (s, 1H), 8.02 (m, 1H), 7.95 (m, 2H), 7.59 (m, 2H), 6.59 (m, 2H), 6.53 (m, 2H), 4.22 (m, 2H), 3.99 (m, 2H), 3.48 (dd, 1H, *J*=3.3, 14.2 Hz), 3.10 (m, 1H), 2.70 (m, 1H), 2.20 (m, 1H), 1.45–1.95 (m, 3H), 1.29 (t, 3H, *J*=6.1 Hz); IR (KBr): 3404, 2937, 2860, 1728, 1649, 1570, 1529, 1475, 1431, 1254 cm⁻¹; HRMS(EI) Calcd for C₂₅H₂₄N₄O₅ 460.1747; Found 460.1738. [α]_D²⁰ = +55° (c=1.78, CH₃OH).

2,3-di(furan-2-yl)-6-(pyrrolidin-1-yl) carbonylamino quinoxaline (GW5) GW5 was prepared by using a method similar to that described for the preparation of GW1 except that pyrrolidine was used instead of ethanol. GW5 is a brown amorphous solid (106.9 mg, 95% yield). ¹H NMR (CDCl₃, 400 MHz). δ : 8.18 (dd, 1H, *J*=2.3, 9.2 Hz), 8.02 (m, 2H), 7.60 (m, 2H), 6.68 (s, 1H), 6.65 (d, 1H, *J*=3.4 Hz), 6.60 (dd, 1H, *J*=0.7, 3.4 Hz), 6.55 (m, 2H), 3.53 (t, 4H, *J*=6.6 Hz), 2.00 (t, 4H, *J*=6.6 Hz); IR (KBr): 3404, 2970, 2877, 1672, 1568, 1525, 1502, 1429, 1382, 1340, 1203 per cm; HRMS(EI) Calcd for C₂₁H₁₈N₄O₃ 374.1379; Found 374.1360.

2,3-di(furan-2-yl)-6-morpholinocarbonylamino quinoxaline (GW6) GW6 was prepared by using a method similar to that described for the preparation of GW1 except that morpholine was used instead of ethanol. GW6 was a yellow amorphous solid (101.4 mg, 87% yield). ¹H NMR (CDCl₃, 400 MHz). δ : 7.96–8.06 (m, 3H), 7.60 (m, 2H), 6.99 (s, 1H), 6.66 (dd, 1H, *J*=0.8, 3.5 Hz), 6.63 (dd, 1H, *J*=0.8, 3.5 Hz), 6.56 (m, 2H), 3.77 (t, 2H, *J*=4.9 Hz), 3.56 (t, 2H, *J*=4.9 Hz), 1.80 (b, 4H); IR (KBr): 3423, 2920, 2852, 1653, 1529, 1475, 1429, 1333, 1254 per cm; HRMS(EI) Calcd for C₂₁H₁₈N₄O₄ 390.1328; Found 390.1309.

2,3-di(furan-2-yl)-6-*N*-(*N*',*N*'-diisopropylcarbamoyl) amino quinoxaline (GW7) GW7 was prepared by using a method similar to that described for the preparation of GW1 except that diisopropylamine was used instead of ethanol. GW7 is a brown amorphous solid (43.9 mg, 36% yield). ¹H NMR (CDCl₃, 400 MHz). δ : 7.99–8.06 (m, 2H), 7.90 (d, 1H, *J*=2.3 Hz), 7.57 (m, 2H), 6.76 (s, 1H), 6.59 (m, 2H), 6.51 (m, 2H), 3.99 (m, 2H), 1.32 (d, 12H, *J*=6.9 Hz); IR (KBr): 3427, 2968, 2928, 1647, 1566, 1520, 1495, 1433, 1375, 1205 per cm; HRMS

(EI) Calcd for $C_{23}H_{24}N_4O_3$ 404.1848; Found 404.1857.

Preparation of His-tagged human CypA protein All cloning techniques including polymerase chain reaction (PCR), restriction, ligation, *E. coli* transformation, and plasmid DNA preparation were carried out according to standard methods^[21]. The His-tagged CypA protein was expressed and purified from the plasmid pQE30-CypA according to the published procedure^[22].

Preparation of rat CypD protein The plasmid pcDNA3.1(+)/Zeo-CypD was kindly provided by Dr James D LECHLEITER (University of Texas Health Science Center, U3SA). By using the forward primer 5'-ATAGAATTCATGCTAGCTCTGCGCTGCG-3' (containing an *EcoRI* site) and the reverse primer 5'-ATATCTCGAGGCTCAACTGGCCACAGTC-3' (containing an *XhoI* site), the PCR product was subcloned into the vector pGEX-4T-1 between the *EcoRI* and *XhoI* sites to obtain the expression plasmid pGEX-4T-1-CypD. Sequencing was carried out to confirm the insertion.

E. coli strains were prepared in Luria-Bertani medium containing 100 mg/mL ampicillin. BL21 (DE3) bacteria transformed with pGEX-4T-1-CypD were grown until the OD₆₀₀ reached 0.8, and isopropylthio- β -D-galactoside (IPTG) was added to a final concentration of 0.2 mmol/L to induce GST-CypD expression at 25 °C overnight.

Bacteria were harvested and lysed by sonication in a sonication buffer [1×phosphate-buffered saline (PBS), 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), pH 7.3, 1 mmol/L ethylenediamine tetraacetic acid (EDTA), 1% Triton X-100]. The bacterial lysate was centrifuged and the supernatant was collected. GST-CypD protein was purified by using a glutathione Sepharose 4B column (Amersham Biosciences, Uppsala, Sweden), and the purified CypD protein was obtained by the on-column cleavage of GST-CypD using thrombin according to the instructions given by the manufacturers of the glutathione Sepharose 4B column (Amersham Biosciences). The purity of the obtained CypD protein was verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis as a single band.

Surface plasmon resonance technology-based Biacore 3000 analyses The interactions between compounds GW1-7 and CypD (A) were performed using the dual flow cell Biacore 3000 instrument (Biacore AB, Uppsala, Sweden). All the experiments were carried out using HBS-EP (10 mmol/L *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid [HEPES], 150 mmol/L NaCl, 3.4 mmol/L EDTA and 0.005% surfactant P20 at pH 7.4) as a running buffer at a constant flow rate of 20 μ L/min at 25 °C. The protein was immobilized directly and covalently on the hydrophilic carboxymethylated dextran matrix of the CM5 sensor chip (BIAcore) by using

the standard primary amine coupling reaction. The protein to be bound to the sensor chip was diluted in 10 mmol/L sodium acetate buffer (pH 6.5) to a concentration of 17 μ mol/L. The concentrations of the compounds dissolved in the running buffer varied from 1.18 to 10 μ mol/L. All the data analyses were carried out using BIAevaluation software, and the sensorgrams were processed by automatic correction for nonspecific bulk refractive index effects. The kinetic analyses of the ligand binding to the protein were performed based on the 1:1 Langmuir binding fit model according to the procedures described in the software manual.

Fluorescence titration assay Fluorescence measurements were performed on a Hitachi (Tokyo, Japan) F-2500 fluorescence spectrophotometer equipped with a thermal controller. The change in the intrinsic tryptophan fluorescence when the compound bound to the protein (CypA or CypD) was monitored using a procedure similar to that described in the literature^[23,24]. The experiments were carried out at 25 °C in PBS (pH 7.3) with the protein concentration set at 13 μ mol/L and the compound concentrations varied from 0 to 40 μ mol/L. The compounds were prepared in dimethylsulfoxide as a stock solution of 10 mmol/L. The fluorescent absorption was recorded with excitation at 280 nm and emission at 340 nm.

PPIase inhibition activity assay The PPIase activity assay for the proteins CypA and CypD was performed based on a published method^[25] with some modifications. The substrate *N*-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Suc-AAPF-pNA, S-7388) and α -chymotrypsin (C-7762) were purchased from Sigma (St Louis, Missouri, USA). Suc-AAPF-pNA was dissolved in tetrahydrofuran containing 400 mmol/L of LiCl, and the stock solution concentration was 10 mmol/L. α -chymotrypsin was dissolved in 1 mmol/L HCl containing 2 mmol/L $CaCl_2$, and the stock solution concentration was 80 mmol/L. The assay buffer (173 μ L of 50 mmol/L HEPES, 100 mmol/L NaCl; pH 8.0 at 0 °C; final concentration 43 mmol/L HEPES, 86 mmol/L NaCl), 15 μ L of de-ionized water and CypD (2 μ L of a 2700 nmol/L stock solution) and the compounds (final concentration ranging from 100 nmol/L to 50 μ mol/L) were pre-equilibrated for 3 h on ice. Immediately before the assay was started, 7.5 μ L of chymotrypsin solution was added. Absorbance readings at 390 nm were recorded when 2.5 μ L of the peptide substrate was added into the 1 cm path length cuvette and the solution was mixed rapidly. The data were collected on a Hitachi U2010 spectrophotometer.

Rat liver mitochondrial swelling and Ca^{2+} uptake/release inhibition assays The mitochondrial swelling and Ca^{2+} uptake/release inhibition assays were carried out according to published methods^[26]. The mitochondria were isolated

by differential centrifugation from the livers of adult Wistar rats (180–200 g) after overnight starvation treatment. The rat livers were excised and washed with 0.25 mol/L sucrose. The fat and connective tissue were removed, and the livers were homogenized (1/10, w/v) using buffer A (250 mmol/L mannitol, 0.5 mmol/L EDTA, 5 mmol/L HEPES, 0.1% bovine serum albumin; pH 7.4) on ice. The homogenate was centrifuged at 1000×g for 10 min in a Biofuge Stratos centrifuge (Hereus Company, Hanau, Germany). The sediment was discarded and the supernatant was centrifuged at 1000×g for 10 min twice. The collected supernatant was then further centrifuged at 10 000×g for 15 min. The pellet (mitochondrial fraction) was resuspended in the test buffer (250 mmol/L mannitol, 70 mmol/L sucrose, 5 mmol/L HEPES; pH 7.4). The total mitochondrial protein was determined by using the Lowry assay using bovine serum albumin as a standard. Rat mitochondria were added to the test buffer to yield a final concentration of 0.5 mg protein per mL^[27]. The tested compounds (100 μmol/L) were mixed with mitochondria for 1 h before CaCl₂ (200 μmol/L) was added. Mitochondrial swelling was determined by monitoring absorbance at 540 nm using a Hitachi U2010 spectrophotometer and the mitochondrial Ca²⁺ uptake/release assay was monitored using a Hitachi F-2500 fluorescence spectrophotometer as described previously^[26].

Molecular modeling and docking The CypD sequence from *Rattus norvegicus* was retrieved from GenBank (GenBank protein ID U68544; <http://www.ncbi.nlm.nih.gov>). The CLUSTAL W program was used to carry out sequence alignment between the sequences of CypD from *Rattus norvegicus* and human CypA^[28]. The sequence similarity identity between CypD and CypA was 63%, and positives were 81%, making the Protein Data Bank (PDB) of human CypA an ideal template for CypD 3-D model building. The 3-D model of the TrpRS was generated based on PDB templates 1AK4^[29], 1AWT^[30], and 1NMK^[31] retrieved from the Protein Data Bank by using the MODELLER program^[32] encoded in Insight II^[33]. MODELLER uses a spatial restraint method to build up 3-D protein models. The structure of each template protein was used to derive spatial restraints expressed as probability density functions for each of the restrained features of the models. The structure with the lowest violation score and lowest energy score was chosen as the candidate. Refinements of the routine in the Homology module of Insight II were used to adjust the positions of the side chains. Finally, the structural models were optimized using Amber force field^[34] with the following parameters: a distance-dependent dielectric constant of 4.0, nonbonded cut-off 10 Å, and Kollman-all-atom charges^[34].

The structures were first minimized by steepest descent, then by conjugating the gradient method to the energy gradient root-mean-square <0.05 kcal·(mol·Å)⁻¹. Several structural analysis software packages were used to check the structure quality. The Prostat module of Insight II was used to analyze the bonds, angles and torsions. The Profile-3D program^[35] was used for checking the structure and sequence compatibility. The 3-D structures of the compounds GW1–7 were constructed from scratch by Sybyl 6.8^[36], and optimized to energy convergence with the Tripos force field and MMFF94 charges.

The major residues possibly comprising the binding site of CypD were identified by sequence alignment with human CypA, and the SiteID program encoded in Sybyl 6.8^[36]. The surface structure of the binding pocket was constructed by using the MOLCAD module of Sybyl 6.8.

The DOCK suite of programs is designed to find possible orientations of a ligand in a “receptor” site^[37]. The orientation of a ligand is evaluated with a shape-scoring function and/or a function approximating the ligand-receptor binding energy. The shape-scoring function is an empirical function resembling the van der Waals’ attractive energy. The ligand-receptor binding energy is taken to be approximately the sum of the van der Waals’ and electrostatic interaction energies. After the initial orientation and scoring evaluation, a grid-based rigid body minimization is carried out for the ligand to locate the nearest local energy minimum within the receptor binding site. The position and conformation of each docked molecule were optimized using the single anchor search and torsion minimization method of DOCK 4.0. Thirty conformations per ligand building a cycle and 50 maximum anchor orientations were used in the anchor-first docking algorithm. All docked configurations were energy minimized using 100 maximum iterations and one minimization cycle.

Results and Discussion

Synthesis of the compounds Generally, the compounds GW1–7 were synthesized as outlined in Scheme 1.

Kinetic analysis of CypD (A) binding to GW1–7 by surface plasmon resonance In order to perform kinetic analyses of the binding of GW1–7 to CypD and CypA, the Biacore 3000 instrument (based on surface plasmon resonance [SPR] technology) was used. As a typical example, the Biacore sensorgrams for the binding of GW2 to the immobilized CypD are shown in Figure 2. The 1:1 Langmuir binding fit model was used for determining the equilibrium dissociation constant (K_D), and the association (k_{on}) and dissociation (k_{off}) rate constants by using Equations (1) and (2).

$$\frac{dR}{dt} = k_{\text{on}} \times C \times (R_{\text{max}} - R) - k_{\text{off}} \times R \quad (1)$$

where R represents the response unit, C is the concentration of the analyte, and

$$K_{\text{D}} = k_{\text{off}}/k_{\text{on}} \quad (2)$$

The obtained results were evaluated by χ^2 analysis. All the kinetic parameters are listed in Table 1.

The Biacore results show that all the 7 tested compounds exhibited strong binding affinities with CypD, with K_{D} values approximately 3–6 $\mu\text{mol/L}$. Due to the high structural homology of CypD and CypA, the tested compounds had high binding affinities with CypA, as indicated in Table 1. However, compound GW5 exhibited higher binding specificity with CypD than with CypA. This was further verified by the intrinsic fluorescence titration analysis and cyclophilin PPIase activity inhibition assay as shown in Tables 2 and 3. Structurally, the R group of the compound (Scheme 1) might play an important role in the ligand binding selectivity for CypD over CypA.

In addition, the K_{D} values obtained from the Biacore assay agreed with the apparent equilibrium dissociation constants (K_{D}) from the intrinsic fluorescence titration analysis




Figure 2. Sensorgrams of the binding of GW2 to CypD measured by the Biacore assay. Representative sensorgrams obtained from the injection of GW2 at concentrations of 1.18, 1.68, 2.40, 3.43, 4.90, 7.00, and 10.00 $\mu\text{mol/L}$ over CypD immobilized on the CM5 chip.

and the IC_{50} values in the cyclophilin PPIase activity inhibition determination as shown in Tables 2 and 3. In agreement with Huber *et al*^[38], we suggest that Biacore is a powerful and useful method for screening cyclophilin inhibitors.

Table 1. Kinetic parameters of GW1–7 binding to CypD and CypA (in parentheses) as analyzed using Biacore 3000.

Compound	R_{max}	$k_{\text{on}}/\text{mol}\cdot\text{L}^{-1}\cdot\text{s}^{-1}$	$k_{\text{off}}/\text{s}^{-1}$	$K_{\text{D}}/\mu\text{mol}\cdot\text{L}^{-1}$	χ^2
GW1	50.9 (49.3)	$3.57\pm 0.25\times 10^3$ ($3.82\pm 0.17\times 10^3$)	$2.16\pm 0.05\times 10^{-2}$ ($9.28\pm 0.21\times 10^{-3}$)	6.05 ± 0.21 (24.3 ± 0.91)	0.52 (0.552)
GW2	48.7 (47.6)	$3.14\pm 0.17\times 10^3$ ($4.73\pm 0.19\times 10^3$)	$2.13\pm 0.04\times 10^{-2}$ ($1.25\pm 0.02\times 10^{-2}$)	6.77 ± 0.22 (26.4 ± 0.87)	0.626 (0.841)
GW3	52.7 (54.6)	$1.99\pm 0.12\times 10^3$ ($1.28\pm 0.09\times 10^3$)	$6.39\pm 0.04\times 10^{-3}$ ($4.79\pm 0.17\times 10^{-3}$)	3.20 ± 0.11 (3.74 ± 0.12)	0.337 (0.862)
GW4	54.7 (57.2)	$3.69\pm 0.21\times 10^3$ ($2.09\pm 0.13\times 10^3$)	$1.81\pm 0.03\times 10^{-2}$ ($7.96\pm 0.16\times 10^{-3}$)	4.89 ± 0.12 (3.81 ± 0.22)	0.467 (1.34)
GW5	56.3 (51.3)	$1.11\pm 0.09\times 10^3$ ($2.59\pm 0.12\times 10^3$)	$2.36\pm 0.06\times 10^{-3}$ ($6.22\pm 0.07\times 10^{-2}$)	2.13 ± 0.17 (24.0 ± 0.78)	0.675 (1.02)
GW6	58.6 (58.7)	$3.49\pm 0.13\times 10^3$ ($6.81\pm 0.22\times 10^3$)	$1.24\pm 0.03\times 10^{-2}$ ($4.66\pm 0.09\times 10^{-2}$)	3.55 ± 0.18 (6.84 ± 0.11)	0.569 (0.903)
GW7	57.8 (50.7)	$2.79\pm 0.15\times 10^3$ ($3.78\pm 0.08\times 10^3$)	$8.06\pm 0.04\times 10^{-3}$ ($1.68\pm 0.04\times 10^{-2}$)	2.89 ± 0.20 (4.44 ± 0.21)	0.574 (0.697)

R_{max} , maximum analyte binding capacity; k_{on} , association rate constant; k_{off} , dissociation rate constant; K_{D} , equilibrium dissociation constant. $K_{\text{D}}=k_{\text{off}}/k_{\text{on}}$; χ^2 , statistical value in Biacore.

Table 2. Apparent equilibrium dissociation constants (K_D') of the binding of GW1–7 to CypD and CypA evaluated by using the tryptophan fluorescence quenching method.

Cyclophilin	Compound (K_D' in $\mu\text{mol/L}$)						
	GW1	GW2	GW3	GW4	GW5	GW6	GW7
CypD	5.60±0.19	6.49±0.20	3.00±0.13	5.51±0.17	2.02±0.09	3.23±0.12	2.52±0.11
CypA	11.32±0.13	11.64±0.16	4.02±0.08	4.76±0.08	20.9±0.18	7.18±0.12	4.22±0.09

K_D' , apparent equilibrium dissociation constant.

Table 3. IC_{50} values of compounds GW1–7 in the inhibition of the PPIase activities of CypA and CypD.

Cyclophilin	Compound (K_D' in $\mu\text{mol/L}$)						
	GW1	GW2	GW3	GW4	GW5	GW6	GW7
CypD	6.17±0.11	7.18±0.13	3.24±0.09	4.09±0.10	1.34±0.07	3.78±0.10	2.15±0.09
CypA	13.66±0.22	14.62±0.26	2.74±0.09	3.16±0.10	21.39±0.31	6.34±0.13	4.80±0.12

Intrinsic fluorescence titration analysis of compounds binding to CypD(A)

Because both of the binding sites of CypD and CypA have a tryptophan residue (Trp 124 for CypD and Trp 121 for CypA), we investigated the binding affinities of the tested compounds for CypD and CypA by using an intrinsic fluorescence titration technique^[23]. During the assay, a 1:1 ratio of CypD(A) to binding compound was used based on published information about CypA/CSA interactions^[39,40] and the results of our molecular docking analyses. The apparent equilibrium dissociation constant (K_D') used for evaluating CypD(A) binding affinity to the tested compound was calculated according to the method in the literature^[23]. We assumed that a 50% occupancy of CypD (or CypA) is set at a fractional fluorescence change of 0.5 ($FC_{0.5}$), and at this point the concentration of the bound ligand is equal to that of the bound protein, which is half of the total concentration of protein. Accordingly, K_D' is equal to the total ligand concentration minus the concentration of the bound protein at $FC_{0.5}$ ^[23].

Figure 3 shows the typical tryptophan fluorescence quenching of CypD induced by titration of the tested compounds with an increase in their concentration. Since none of the compounds showed any intrinsic fluorescence absorption, their possible effects on the experiments could be discounted (data not shown). The K_D' values of GW1–7 are summarized in Table 2. Obviously, the binding selectivity of GW5 for CypD over CypA could also be determined, and the K_D' values are very comparable to the K_D values determined by the Biacore assay.




Figure 3. Tryptophan fluorescence quenching by compounds binding to CypD. CypD (13 mmol/L) was incubated with increasing amounts of GW1–7, respectively. ▲, GW1, 0–30 $\mu\text{mol/L}$; ▼, GW2, 0–30 $\mu\text{mol/L}$; ■, GW3, 0–40 $\mu\text{mol/L}$; ●, GW4, 0–40 $\mu\text{mol/L}$. The data for GW5–7 are not shown here for clarity. The resulting fluorescence change is plotted as a fraction of the maximal change.

CypD (A) PPIase activity inhibition assay Both CypD and CypA belong to the PPIase family, and classic spectrophotometric methods^[41] can be used to determine the PPIase inhibition activity of GW1–7 against CypD and CypA. During the assay, the rate constants for the *cis-trans* interconversion were evaluated by fitting the data to the integrated first-order rate equation by nonlinear least-square analysis^[25,41].

As a typical example, Figure 4 shows the CypD PPIase inhibition results with increases in the concentrations of the




Figure 4. CypD PPIase activity inhibition assay for GW1–7. PPIase (26 nmol/L) was pre-incubated with the tested compound at a number of concentrations, and the PPIase activity change was plotted as a fraction of the maximal change. ▲, GW1 (1.0, 1.25, 2.5, 5.0, 7.5, 10.0, 12.5, 25.0, 50.0 $\mu\text{mol/L}$); ▼, GW2 (1.0, 2.5, 3.75, 5.0, 7.5, 10.0, 12.5, 25.0, 50.0 $\mu\text{mol/L}$); ■, GW3 (0.1, 0.5, 1.0, 1.25, 2.5, 3.75, 5.0, 7.5, 10.0, 25.0 $\mu\text{mol/L}$); ●, GW4 (0.1, 0.5, 1.0, 1.25, 2.5, 3.75, 5.0, 7.5, 10.0, 25.0 $\mu\text{mol/L}$); ►, GW5 (0.1, 0.5, 1.0, 2.5, 5, 7.5, 10.0, 25.0, 50.0 $\mu\text{mol/L}$); ◆, GW6 (0.1, 0.5, 1.0, 2.5, 5, 7.5, 10.0, 25.0, 50.0 $\mu\text{mol/L}$); ◄, GW7 (0.1, 0.5, 1.0, 2.5, 5, 7.5, 10.0, 25.0, 50.0 $\mu\text{mol/L}$).

compounds, and Table 3 shows the IC_{50} values of GW1–7 against CypD and CypA. The fact that the IC_{50} values accord well with the Biacore and fluorescence titration results (Tables 1, 2) confirms the reliability of these three detection approaches.

Rat Ca^{2+} -dependent mitochondrial swelling and Ca^{2+} uptake/release inhibition assays In general, MPT pores are open when mitochondria encounter abnormally high concentrations of exogenous Ca^{2+} ions. These pores allow solutes of <1500 Da in size across the inner mitochondrial membrane, leading to mitochondrial swelling. Such swelling can be detected by time scans of absorbance at 540 nm (A_{540}) and the extent of swelling is proportional to A_{540} ^[26].

Fluo-5N fluorescence is quite low without binding to Ca^{2+} in controls, because the high mitochondrial membrane potential prevents the release of endogenous mitochondrial Ca^{2+} . When exogenous Ca^{2+} was added, Fluo-5N fluorescence increased immediately and decreased rapidly as Ca^{2+} ions were taken up into the mitochondria. Subsequently, the accumulation of cations in the mitochondria led to mitochondrial swelling and depolarization. Ca^{2+} ions were then released from mitochondria as a consequence of the onset of MPT, as indicated by an increase in Fluo-5N fluorescence. Ca^{2+} release was completely blocked by 1 $\mu\text{mol/L}$ CSA. Fluo-5N fluorescence also revealed that compounds GW1–7 inhibited the uptake/release of exogenously added Ca^{2+} to a




Figure 5. Ca^{2+} -dependent mitochondrial swelling and Fluo-5N fluorescence after induction of MPT with CaCl_2 . Mitochondria (0.5 mg/mL) were mixed with CSA (1 $\mu\text{mol/L}$) (as a control) or the compounds GW1–7 (100 $\mu\text{mol/L}$ for each). The symbols (+) and (–) represent the solution with or without 200 $\mu\text{mol/L}$ of CaCl_2 , respectively. Absorbance changes at 540 nm (A) and Fluo-5N fluorescence excited at 485 nm (B) were monitored soon after CaCl_2 (200 $\mu\text{mol/L}$) was added, as described in the text.

certain extent.

Figure 5A shows the results of the rat mitochondrial swelling inhibition assay for GW1–7 (100 $\mu\text{mol/L}$) with CSA (1 $\mu\text{mol/L}$) as a control. Figure 5B gives the results of the mitochondrial Ca^{2+} uptake/release inhibition assay for GW1–7 (100 $\mu\text{mol/L}$). The results show that the inhibition abilities of compounds GW1–7 against Ca^{2+} uptake/release are in good agreement with their inhibition abilities against mitochondrial swelling. We found that compounds GW2, 5, 6, and 7 had a strong ability, whereas GW1, 3, and 4 did not have any inhibition activity, which could be because of the R group. Compared with GW2, 5, 6, and 7, the tails of GW1, 3, and 4 were ethoxycarbonyl, which might prevent them from transferring into mitochondria through the membranes or cause the loss of inhibition ability for other (unclear) reasons. The behavior of CypD in mitochondria is much more complicated

than that of the purified CypD protein, so the different R groups might cause different results. CSA had the highest inhibition activity, and the relative general inhibition abilities of the other compounds were: GW5>GW7>GW6>GW2. Such a sequence seems to be consistent with the CypD PPIase inhibition ability of the compounds (Table 3). This result thus confirms the fact that CypD inhibitors may possess possible inhibition activity against Ca^{2+} -dependent MPT pore opening.

Molecular docking analyses To gain further insight into the CypD(A)/inhibitor interaction model at the atomic level, docking analysis based on molecular modeling was carried out without the published rat CypD crystal data. Our rat CypD model tallies very well with the human CypD crystal [PDB ID: 2bit] structure shown in Figure 6A. The weighted root mean square distance is 0.6040 and the identity score is 95.7%. Because of the similar structures of the compounds, they share the same precursor, with some overlapping structural elements in common (Figure 6B). Similar to CypA, the binding pocket of CypD is also fairly large and shallow, and is composed of residues Arg58, Ile60, Phe63, Met64, Glu66, Gly75, Thr76, Gly77, Ala104, Asn105, Ala106, Gln114, Phe116, Thr122, Trp124, Leu125, Lys128, and His129. GW1–7 and CSA bind to the same binding site of CypD. Unlike the case of full occupation by CSA, GW1–7 occupied only part of the binding pocket and might swing in the pocket. Helekar and Patrick even demonstrated that Arg55 of CypA was a key determinant against PPIase activity^[42]. Compounds GW1–7 showed their hydrophobic contact with Arg58 of CypD (Arg55 of CypA). Therefore, the PPIase activity of CypD could be inhibited by hydrophobic interactions with the inhibitors. In addition, GW1–7 formed stacking interactions with Trp124 of CypD (Trp121 of CypA) and the only tryptophan residues of CypD and CypA that contribute to the change in fluorescence intensity (data not shown).

Conclusion In this work, we reported on 7 small quinoxaline derivatives as novel CypD inhibitors. *In vitro* assays indicated that compounds GW2, 5, 6, and 7 inhibit Ca^{2+} -dependent rat liver mitochondrial swelling and Ca^{2+} uptake/release. By using SPR and fluorescence titration techniques, kinetic analysis of CypD/inhibitor interactions were quantitatively performed. The measured IC_{50} values for the tested compounds are all in good agreement with the SPR and fluorescence titration results, which suggests that these are powerful methods for identifying CypD inhibitors^[38]. Further studies indicated that GW5 has binding selectivity for CypD over CypA.

In summary, in this present work we used an appropriate and powerful approach for identifying CypD inhibitors, and




Figure 6. Overlapping of the rat CypD model/human CypD crystal data (A) and GW1–7 in the binding pocket of rat CypD (B).

developed a small compound that shows specific ligand-binding ability for CypD, which could be used in the inhibition of MPT pore opening.

Acknowledgements

We thank Dr James D LECHLEITER for providing the rat CypD gene and Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) for providing human cyclophilin D structure information.

References

- Liu X, Kim CN, Yang J, Jemerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. *Cell* 1996; 86: 147–57.
- Susin SA, Lorenzon HK, Zamzami N, Marzo I, Snow BE, Brothers GM, *et al*. Molecular characterization of mitochondrial apoptosis-inducing factor. *Nature* 1999; 397: 441–6.
- Olson M, Kornbluth S. Mitochondria in apoptosis and human disease. *Curr Mol Med* 2001; 1: 91–122.
- Crompton M. Mitochondria and aging: a role for the permeability transition? *Aging Cell* 2004; 3: 3–6.
- Waldmeier PC, Zimmermann K, Qian T, Tintelen-Blomley M, Lemasters JJ. Cyclophilin D as a drug target. *Curr Med Chem* 2003; 10: 1485–506.
- Mattson MP, Kroemer G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. *Trends Mol Med* 2003; 9: 196–205.
- Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? *J Neurosci Res* 2005; 79: 231–9.
- Crompton M. On the involvement of mitochondrial intermembrane junctional complexes in apoptosis. *Curr Med Chem* 2003; 10: 1473–84.
- Connern CP, Halestrap AP. Purification and N-terminal sequencing of peptidyl-prolyl *cis-trans*-isomerase from rat liver mitochondrial matrix reveals the existence of a distinct mitochondrial cyclophilin. *Biochem J* 1992; 284: 381–5.
- Fischer G, Wittmann-Liebold B, Lang K, Kieffhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl *cis-trans* isomerase are probably identical proteins. *Nature* 1989; 337: 476–8.
- Lin DT, Lechleiter JD. Mitochondrial targeted cyclophilin D protects cells from cell death by peptidyl prolyl isomerization. *J Biol Chem* 2002; 277: 31134–41.
- Li Y, Johnson N, Capano M, Edwards M, Crompton M. Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis. *Biochem J* 2004; 383: 101–9.
- Schubert A, Grimm S. Cyclophilin D, a component of the permeability transition-pore, is an apoptosis repressor. *Cancer Res* 2004; 64: 85–93.
- Machida K, Osada H. Molecular interaction between cyclophilin D and adenine nucleotide translocase in cytochrome c release: does it determine whether cytochrome c release is dependent on permeability transition or not? *Ann NY Acad Sci* 2003; 1010: 182–5.
- Crompton M. The mitochondrial permeability transition pore and its role in cell death. *Biochem J* 1999; 341: 233–49.
- Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. *Biochimie* 2002; 84: 153–66.
- Crompton M, Costi A. Kinetic evidence for a heart mitochondrial pore activated by Ca²⁺, inorganic phosphate and oxidative stress. A potential mechanism for mitochondrial dysfunction during cellular Ca²⁺ overload. *Eur J Biochem* 1988; 178: 489–501.
- Crompton M, Barksby E, Johnson N, Capono M. Mitochondrial intermembrane junctional complexes and their involvement in cell death. *Biochimie* 2002; 84: 143–52.
- Alaimo RJ [inventor]. Norwich Eaton Pharmaceuticals [assignee]. Thiocyanatoquinoxaline compounds with immunomodulating activity. US patent 4540693. September 10, 1985.
- Magnus P, Thurston LS. Synthesis of the vinblastine-like antitumor bis-indole alkaloid navelbine analogue desethylidihydrovelbine. *J Org Chem* 1991; 56: 1166–70.
- Sambrook J, Fritsch EF, Maniatis T. *Molecular Cloning: A Laboratory Manual*. 2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989.
- Luo C, Luo H, Zheng S, Gui C, Yue L, Yu C, *et al*. Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. *Biochem Biophys Res Commun* 2004; 321: 557–65.
- Husi H, Zurini MGM. Comparative binding studies of cyclophilins to cyclosporin A and derivatives by fluorescence measurement. *Anal Biochem* 1994; 222: 251–5.
- Handschumacher RE, Harding MW, Rice J, Drugge RJ. Cyclophilin A: a specific cytosolic binding protein for cyclosporin A. *Science* 1984; 226: 544–7.
- Kofron JL, Kuzmic P, Kishore V, Colon-Bonilla E, Rich DH. Determination of kinetic constants for peptidyl prolyl *cis-trans* isomerases by an improved spectrophotometric assay. *Biochemistry* 1991; 30: 6127–34.
- Blattner JR, He L, Lemasters JJ. Screening assays for the mitochondrial permeability transition using a fluorescence multiwell plate reader. *Anal Biochem* 2001; 295: 220–6.
- Lowry OH, Rosenbrough NH, Farr AL, Randall JR. Protein measurement with the folin phenol reagent. *J Biol Chem* 1951; 193: 265–75.
- Thompson J, Higgins D, Gibson T. CLUSTAL_W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 1994; 22: 4673–80.
- Gamble T, Vajdos F, Yoo S, Worthylake D, Houseweart M, Sundquist WI, *et al*. Crystal structure of human cyclophilin a bound to the amino-terminal domain of HIV-1 capsid. *Cell* 1996; 87: 1285–94.
- Vajdos F, Yoo S, Houseweart M, Sundquist W, Hill C. Crystal structure of cyclophilin a complexed with a binding site peptide from the HIV-1 capsid protein. *Protein Sci* 1997; 6: 2297–307.
- Sedrani R, Kallen J, Martin Cabrejas L, Papageorgiou C, Senia F, Rohrbach S, *et al*. Sangliferrin-cyclophilin interaction: degradation work, synthetic macrocyclic analogues, x-ray crystal structure and binding data. *J Am Chem Soc* 2003; 125: 3849–59.
- Sali A, Blundell T. Comparative protein modelling by satisfaction of spatial restraints. *J Mol Biol* 1993; 234: 779–815.
- Insight II [molecular modeling package]. San Diego, California, the United States: Molecular Simulations; 2000.
- Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, *et al*. A Second generation force field for the simulation of proteins, nucleic acids, and organic molecules. *J Am Chem Soc* 1995; 117: 5179–97.
- Bowie JU, Luthy R, Eisenberg D. A method to identify protein sequences that fold into a known three-dimensional structure. *Science* 1991; 253: 164–70.
- Sybyl [molecular modeling package]. St Louis, MO: Tripos Associates; 2000.
- Ewing T, Kuntz ID. Critical evaluation of search algorithms for automated molecular docking and database screening. *J Comput*

- Chem 1997; 18: 1175–89.
- 38 Huber W, Persicace S, Kohler J, Muller F, Schlatter D. SPR-based interaction studies with small molecular weight ligands using hAGT fusion proteins. *Anal Biochem* 2004; 333: 280–8.
- 39 Kallen J, Spitzfaden C, Zurini MGM, Wider G, Widmer H, Wuthrich K, *et al*. Structure of human cyclophilin and its binding site for cyclosporin A determined by X-ray crystallography and NMR spectroscopy. *Nature* 1991; 353: 276–9.
- 40 Pfluefel G, Kallen J, Schirmer T, Jansonius JN, Zurini MGM, Walkinshaw MD, *et al*. X-ray structure of a decameric cyclophilin-cyclosporin crystal complex. *Nature* 1993; 361: 9–4.
- 41 Fischer G, Berger E, Bang H. Kinetic β -deuterium isotope effects suggest a covalent mechanism for the protein folding enzyme peptidylprolyl *cis/trans*-isomerase. *FEBS Lett* 1989; 250: 267–70.
- 42 Helekar S, Patrick J. Peptidyl prolyl *cis-trans* isomerase activity of cyclophilin A in functional homo-oligomeric receptor expression. *Proc Natl Acad Sci USA* 1997; 94: 5432–7.
-

Important Announcement: the Online Manuscript Submission and Review System was Launched!

Acta Pharmacologica Sinica is happy to announce that the online manuscript submission and review system, ScholarOne Manuscript Central (<http://mc.manuscriptcentral.com/aphs>), was launched on May 25, 2005.

As the leading web-based peer-review system, Manuscript Central is a complete, database-driven software for the online submission and review of full-text manuscripts and graphics. The system provides fully electronic workflow and will speed up the time from submission to decision.

We strongly recommend authors to submit manuscript via this system, which enables us to handle your manuscript quickly and efficiently. Please read the User Guide before submitting your manuscript online. For more detailed submission instruction, please consult the Manuscript Central Online User Guide (<http://mcv3help.manuscriptcentral.com/tutorials/>). You may also contact the Editorial Office who will be pleased to help you.